GT Biopharma, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 7.6 million compared to USD 20.88 million a year ago. Basic loss per share from continuing operations was USD 5.64 compared to USD 19.66 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3 USD | -3.45% | -17.81% | -60.78% |
Mar. 26 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 01 | GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.78% | 4.29M | |
+34.00% | 664B | |
+29.29% | 567B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B |
- Stock Market
- Equities
- GTBP Stock
- News GT Biopharma, Inc.
- GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023